To the Editor:
We read with great interest the recently published manuscript by Dessein, et al1 regarding chemerin concentrations and cardiovascular disease (CVD) risk in patients with rheumatoid arthritis (RA). The authors state in their discussion that “chemerin may contribute to the link between inflammation and increased risk of coronary artery disease among nonobese patients with RA. Indeed, systemic inflammation was strongly associated with chemerin concentrations in our analysis, and suppression of inflammation with adalimumab is linked to reduced chemerin concentrations in RA”2.
We would like to …
Address correspondence to Dr. K. Makrilakis, First Department of Propaedeutic/Internal Medicine, Athens University Medical School, Laiko General Hospital, 17 Ag. Thoma St., 11527 Athens, Greece. E-mail: kmakrila{at}med.uoa.gr